Resource Oriented Decision Making for Treatment of Metastatic Colorectal Cancer (mCRC) in a Lower-Middle Income Country: Egyptian Foundation of Medical Sciences (EFMS) Consensus Recommendations 2020

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 ;71(3):209-249. doi: 10.3322/caac.21660.
   Google Scholar
• Lykoudis PM, O’Reilly D, Nastos K, Fusai G. Systematic review of surgical management of synchronous colorectal liver metastases. Br J Surg. 2014;101(6):605–612. doi:10.1002/bjs.9449
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Van Cutsem E, Rougier P, et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer. 2007;43(14):2037–2045. doi:10.1016/j.ejca.2007.07.017
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:1–18. doi:10.1155/2014/437971
   Google Scholar
• Metwally IH, Shetiwy M, Elalfy AF, Abouzid A, Saleh SS, Hamdy M. Epidemiology and survival of colon cancer among Egyptians: a retrospective study. J Coloproctol. 2018;38(1):24–29. doi:10.1016/j.jcol.2017.09.418
   Google Scholar
• Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22(7):1209–1214. doi:10.1200/JCO.2004.11.037
   PubMed Web of Science ®Google Scholar
• Asmis T, Berry S, Cosby R, Chan K, Coburn N, Rother M. Strategies of sequential therapies in unresectable metastatic colorectal cancer: a meta-analysis. Curr Oncol. 2014;21(6):318–328. doi:10.3747/co.21.2146
   PubMed Web of Science ®Google Scholar
• Heinemann V, Von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, Phase 3 trial. Lancet Oncol. 2014;15(10):1065–1075. doi:10.1016/S1470-2045(14)70330-4
   PubMed Web of Science ®Google Scholar
• Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer a randomized clinical trial. JAMA. 2017;317(23):2392–2401. doi:10.1001/jama.2017.7105
   PubMed Web of Science ®Google Scholar
• Piedbois P. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998;16(1):301–308. doi:10.1200/JCO.1998.16.1.301
   PubMed Web of Science ®Google Scholar
• Gabriela Chiorean E, Nandakumar G, Fadelu T, et al. Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline. J Glob Oncol. 2020;6(6):414–438. doi:10.1200/JGO.19.00367
   Web of Science ®Google Scholar
• Jakovljevic M, Gutzwiller F, Schwenkglenks M, et al. Costs differences among monoclonal antibodies-based first-line Oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin’s lymphoma. J BUON. 2014;19(4):1111–1120. doi:10.5167/uzh-117543
   PubMed Web of Science ®Google Scholar
• Cristina W, Silva D, Martin A, et al. Medical cost of colorectal cancer services in Serbia Between 2014 and 2017: national data report. Natl Data Rep Front Pharmacol. 2019;10:526. doi:10.3389/fphar.2019.00526
   PubMed Web of Science ®Google Scholar
• Kovacevic A, Dragojevic-Simic V, Tarabar D, et al. Five-year survival and costs of care in metastatic colorectal cancer: conventional versus monoclonal antibody-based treatment protocols. Expert Rev Anticancer Ther. 2015;15(8):963–970. doi:10.1586/14737140.2015.1059280
   PubMed Web of Science ®Google Scholar
• Marquet JM. Colon cancer. Oncologie. 1999;1(6):343–347.
   Google Scholar
• Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018;29(1):44–70. doi:10.1093/annonc/mdx738
   PubMed Web of Science ®Google Scholar
• German S3-Guideline Colorectal Cancer G. German guideline program in oncology (German Cancer Society, German Cancer Aid, AWMF): S3-Guideline Colorectal Cancer, long version 2.1, 2019, AWMF registrationnumber: 021-007OL; 2019:1–322. Available from: http://www.leitlinienprogramm-onkologie.de/leitlinien/kolorektales-karzinom/. Accessed February 9, 2022.
   Google Scholar
• Elizabeth Murphy AH, Freeman V, Barclay K, et al. Cancer Council Australia Colorectal Cancer Guidelines Working Party (2017) PRP2-5, 7: can peri operative management be optimised? Clinical practice guidelines for the prevention, early detection and management of colorectal cancer; 2018. Available from: https://wiki.cancer.org.au/australiawiki/images/e/ed/Colorectal_cancer_guidelines_short_form.pdf. Accessed February 9, 2022.
   Google Scholar
• Vekic B, Dragojevic-Simic V, Jakovljevic M, et al. A correlation study of the colorectal cancer statistics and economic indicators in selected Balkan Countries. Front Public Health. 2020;8:1–8. doi:10.3389/fpubh.2020.00029
   PubMed Web of Science ®Google Scholar
• Egypt, Arab Rep. | Data. Available from: https://data.worldbank.org/country/EG. Accessed March 12, 2021.
   Google Scholar
• Egypt profiles and briefs. EMRO Regional Health Observatory. Available from: https://rho.emro.who.int/per-country-egy. Accessed December 10, 2021.
   Google Scholar
• Fervers B, Burgers JS, Voellinger R, et al. Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation. BMJ Qual Saf. 2011;20(3):228–236. doi:10.1136/bmjqs.2010.043257
   PubMed Web of Science ®Google Scholar
• Data for Lower middle income, Tunisia | Data. Available from: https://data.worldbank.org/?locations=XN-TN. Accessed September 14, 2021.
   Google Scholar
• Morocco | Data. Available from: https://data.worldbank.org/country/MA. Accessed September 14, 2021.
   Google Scholar
• Sudan | Data. Available from: https://data.worldbank.org/country/SD. Accessed September 14, 2021.
   Google Scholar
• Rosenfeld RM, Nnacheta LC, Corrigan MD. Clinical consensus statement development manual. Otolaryngol Head Neck Surg. 2015;153:S1–S14. doi:10.1177/0194599815601394
   PubMed Web of Science ®Google Scholar
• Nahler G. ECOG performance status. Dict Pharm Med. 2009;60. doi:10.1007/978-3-211-89836-9_452
   Google Scholar
• Mohile SG, Dale W, Somerfield MR, Hurria A. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: Asco guideline for geriatric Oncology summary. J Oncol Pract. 2018;14(7):442–446. doi:10.1200/JOP.18.00180
   PubMed Web of Science ®Google Scholar
• Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104(9):1998–2005. doi:10.1002/cncr.21422
   PubMed Web of Science ®Google Scholar
• Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 2010;21(7):1395–1403. doi:10.1093/annonc/mdp598
   PubMed Web of Science ®Google Scholar
• Funakoshi T, Horimatsu T, Nakamura M, et al. Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan. ESMO Open. 2018;3(2):1–7. doi:10.1136/esmoopen-2017-000301
   Web of Science ®Google Scholar
• Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–e28. doi:10.1016/S1470-2045(19)30718-1
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–1422. doi:10.1093/annonc/mdw235
   PubMed Web of Science ®Google Scholar
• Ulanja MB, Rishi M, Beutler BD, et al. Colon cancer sidedness, presentation, and survival at different stages. J Oncol. 2019;2019(Lcc):1–12. doi:10.1155/2019/4315032
   Web of Science ®Google Scholar
• Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2691 patients in randomized controlled trials. J Clin Oncol. 2008;26(9):1443–1451. doi:10.1200/JCO.2007.14.0509
   PubMed Web of Science ®Google Scholar
• Lonardi S, Schirripa M, Buggin F, et al. First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: the PANDA study. J Clin Oncol. 2020;38(15_suppl):4002. doi:10.1200/jco.2020.38.15_suppl.4002
   Google Scholar
• Adam R, De Gramont A, Figueras J, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus-NICOLAS VAUTHEY OF THE EGOSLIM (EXPERT GROUP ON ONCOSURGERY MANAGEMENT OF LIVER METASTASES) GROUP g Oncologist® Academia-Pharma Intersect: hepatobiliary. Oncologist. 2012;17:1225–1239. doi:10.1634/theoncologist.2012-0121
   PubMed Web of Science ®Google Scholar
• Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759-766. doi:10.1097/00000658-200206000-00002
   Google Scholar
• Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–1215. doi:10.1016/S1470-2045(13)70447-9
   PubMed Web of Science ®Google Scholar
• Tsai M-S, Su Y-H, Ho M-C, et al. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol. 2007;14(2):786–794. doi:10.1245/s10434-006-9215-5
   PubMed Web of Science ®Google Scholar
• Prasanna T, Wong R, Price T, et al. Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. Curr Probl Cancer. 2021;45(1):100637. doi:10.1016/j.currproblcancer.2020.100637
   PubMed Web of Science ®Google Scholar
• Kanemitsu Y, Shimizu Y, Mizusawa J, et al. A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: JCOG0603 study. J Clin Oncol. 2020;38(15_suppl):4005. doi:10.1200/jco.2020.38.15_suppl.4005
   Web of Science ®Google Scholar
• Stahler A, Heinemann V, Holch JW, et al. Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3). Int J Cancer. 2021;149(11):1935–1943. doi:10.1002/ijc.33747
   PubMed Web of Science ®Google Scholar
• Bridgewater JA, Pugh SA, Maishman T, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(3):398–411. doi:10.1016/S1470-2045(19)30798-3
   PubMed Web of Science ®Google Scholar
• Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249(3):420–425. doi:10.1097/SLA.0b013e31819a0486
   PubMed Web of Science ®Google Scholar
• Tomasello G, Petrelli F, Ghidini M, Russo A, Passalacqua R, Barni S. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol. 2017;3(7):1–6. doi:10.1001/jamaoncol.2017.0278
   Web of Science ®Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, et al. Colon Cancer Colon Cancer. NCCN Harmon Guidel Sub-Saharan Africa - Colon Cancer. 2018; Version 2. (Colon Cancer):1-5. J Natl Compr Canc Netw. 2018;16(4):359–369.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Rivera F, O’Neil BH, et al. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. Eur J Cancer. 2016;67:11–20. doi:10.1016/j.ejca.2016.07.019
   PubMed Web of Science ®Google Scholar
• Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. CAP Laboratory Improvement Programs. Am J Clin Pathol. 2017;147(3):221–260. doi:10.5858/arpa.2016-0554-CP
   PubMed Web of Science ®Google Scholar
• Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015;51(5):587–594. doi:10.1016/j.ejca.2015.01.054
   PubMed Web of Science ®Google Scholar
• Boeckx N, Koukakis R, de Beeck KO, et al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol. 2017;28(8):1862–1868. doi:10.1093/annonc/mdx119
   PubMed Web of Science ®Google Scholar
• Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713–1729. doi:10.1093/annonc/mdx175
   PubMed Web of Science ®Google Scholar
• Montagnani F, Chiriatti A, Turrisi G, Francini G, Fiorentini G. A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity. Color Dis. 2011;13(8):846–852. doi:10.1111/j.1463-1318.2010.02206.x
   PubMed Web of Science ®Google Scholar
• Kotani D, Yoshino T, Kotaka M, et al. Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: safety lead-in results from the QUATTRO-II study. Invest New Drugs. 2021;39(6):1649–1655. doi:10.1007/s10637-021-01125-2
   PubMed Web of Science ®Google Scholar
• Guo Y, Shi M, Shen X, Yang C, Yang L, Zhang J. Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis. Clin Colorectal Cancer. 2014;13(2):110–118. doi:10.1016/j.clcc.2013.12.004
   PubMed Web of Science ®Google Scholar
• Berry SR, Cosby R, Asmis T, Chan K, Hammad N, Krzyzanowska MK. Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol. 2015;26(3):477–485. doi:10.1093/annonc/mdu272
   PubMed Web of Science ®Google Scholar
• de Gramont A, Buyse M, Abrahantes JC, et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol. 2007;25(22):3224–3229. doi:10.1200/JCO.2006.10.4380
   PubMed Web of Science ®Google Scholar
• Hochster HS, Grothey A, Hart L, et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Ann Oncol. 2014;25(6):1172–1178. doi:10.1093/annonc/mdu107
   PubMed Web of Science ®Google Scholar
• Botrel TEA, Clark LG, Paladini L, Clark OA. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2016;16(1):1–19. doi:10.1186/s12885-016-2734-y
   Web of Science ®Google Scholar
• Cremolini C, Antoniotti C, Rossini D, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, rand. Lancet Oncol. 2020;21(4):497–507. doi:10.1016/S1470-2045(19)30862-9
   PubMed Web of Science ®Google Scholar
• Sunakawa Y, Sakamoto Y, Inoue E, et al. ANCHOR CRC: a single-arm, Phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer. Ann Oncol. 2020;31:S242–S243. doi:10.1016/j.annonc.2020.04.078
   Web of Science ®Google Scholar
• André T, Shiu -K-K, Kim TW, et al. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–2218. doi:10.1056/nejmoa2017699
   PubMed Web of Science ®Google Scholar
• Modest DP, Martens UM, Riera-Knorrenschild J, et al. FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the randomized, open-label, Phase II Volfi study (AIO KRK0109). J Clin Oncol. 2019;37(35):3401–3411. doi:10.1200/JCO.19.01340
   PubMed Web of Science ®Google Scholar
• Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(11):1077–1085. doi:10.1016/S1470-2045(13)70154-2
   PubMed Web of Science ®Google Scholar
• Kosugi C, Koda K, Denda T, et al. Multicenter phase II clinical study of the efficiency and safety of capecitabine plus intermittent oxaliplatin with bevacizumab as first-line therapy in patients with metastatic colorectal cancer (VOICE trial). Int J Colorectal Dis. 2021;36(12):2637–2647. doi:10.1007/s00384-021-03995-7
   PubMed Web of Science ®Google Scholar
• Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–237. doi:10.1200/JCO.2004.05.113
   PubMed Web of Science ®Google Scholar
• Clarke SJ, Yip S, Brown C, et al. Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; Results of a randomised phase II study (DaVINCI) and meta-analysis. Eur J Cancer. 2011;47(12):1826–1836. doi:10.1016/j.ejca.2011.04.024
   PubMed Web of Science ®Google Scholar
• Valtorta E, Martino C, Sartore-Bianchi A, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015;28(11):1481–1491. doi:10.1038/modpathol.2015.98
   PubMed Web of Science ®Google Scholar
• Shitara K, Yonesaka K, Denda T, et al. Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. Cancer Sci. 2016;107:1843–1850. doi:10.1111/cas.13098
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(14):2311–2319. doi:10.1200/JCO.2007.13.1193
   PubMed Web of Science ®Google Scholar
• Peeters M, Oliner KS, Price TJ, et al. Analysis of KRAS/NRAS mutations in a Phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Cancer Res. 2015;21(24):5469–5479. doi:10.1158/1078-0432.CCR-15-0526
   PubMed Web of Science ®Google Scholar
• Boeckx N, Koukakis R, Op de Beeck K, et al. Effect of primary tumor location on second- or later-line treatment outcomes in patients with RAS wild-type metastatic colorectal cancer and all treatment lines in patients with RAS mutations in four randomized panitumumab studies. Clin Colorectal Cancer. 2018;17(3):170–178.e3. doi:10.1016/j.clcc.2018.03.005
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539–1544. doi:10.1200/JCO.2006.09.6305
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499–3506. doi:10.1200/JCO.2012.42.8201
   PubMed Web of Science ®Google Scholar
• Joulain F, Proskorovsky I, Allegra C, et al. Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. Br J Cancer. 2013;109(7):1735–1743. doi:10.1038/bjc.2013.523
   PubMed Web of Science ®Google Scholar
• Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16(5):499–508. doi:10.1016/S1470-2045(15)70127-0
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer abstract. Vol 357; 2007. Available from: www.nejm.org. Accessed February 9, 2022.
   Google Scholar
• Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658–1664. doi:10.1200/JCO.2006.08.1620
   PubMed Web of Science ®Google Scholar
• Mauri G, Pizzutilo EG, Amatu A, et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat Rev. 2019;73:41–53. doi:10.1016/j.ctrv.2018.12.006
   PubMed Web of Science ®Google Scholar
• Karani A, Felismino TC, Diniz L, Petaccia Macedo M, Souza e Silva V, Abdon Mello C. Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma? A retrospective analysis. Ecancermedicalscience. 2020;14:1–11. doi:10.3332/ecancer.2020.1069
   Web of Science ®Google Scholar
• GONO. A Phase II single-arm study of cetuximab plus irinotecan as rechallenge 3 Rd -line treatment of metastatic colorectal cancer patients progressing after an initial response to a 1st -line cetuximab-containing therapy and a standard 2nd -line the cricket; August, 2014. Available from: https://lion.app.box.com/file/415775152695. Accessed February 9, 2022.
   Google Scholar
• Kopetz S, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). J Clin Oncol. 2020;38(15_suppl):4001. doi:10.1200/jco.2020.38.15_suppl.4001
   Google Scholar
• Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738–746. doi:10.1016/S1470-2045(16)00150-9
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20(4):518–530. doi:10.1016/S1470-2045(18)30904-5
   PubMed Web of Science ®Google Scholar
• Siena S, Di Bartolomeo M, Raghav KPS, et al. A Phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. J Clin Oncol. 2020;38(15_suppl):4000. doi:10.1200/jco.2020.38.15_suppl.4000
   Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–1191. doi:10.1016/S1470-2045(17)30422-9
   PubMed Web of Science ®Google Scholar
• Le DT, Kim TW, van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11–19. doi:10.1200/JCO.19.02107
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520. doi:10.1056/NEJMoa1500596
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Sgouros J, Aravantinos G, Dragasis S, et al. Reintroduction of irinotecan and oxaliplatin as a combination (IROX regimen) in heavily pretreated colorectal cancer patients - A single-center experience. Forum Clin Oncol. 2013;4(3):13–18.
   Google Scholar